NSECertificate under SEBI (Depositories and Participants) Regulations, 20182d ago · 12 Oct 2026, 01:06 pm

Certificate under SEBI (Depositories and Participants) Regulations, 2018

Emcure Pharmaceuticals Limited · EMCURE

✦ AI SummaryRegulatory

Emcure Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming no securities were received for dematerialization during the quarter ended September 30, 2026.

Analysis Scores

Earnings Impact1/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact1/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Emcure Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Attachments (1)

📄

EMCURE_12102026130556_IntimationReg74_5_ofDPRegulation.pdf

pdf

Download →
View document text
Emcure Ref: EPL/CS/SE/0089/2026 Date: October 12, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Confirmation under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026 Please find enclosed herewith a Confirmation Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, received from MUFG Intime India Private Limited, the Registrar and Share Transfer Agent (RTA) of the Company. You are requested to take the same on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary and Compliance Officer ICSI Membership No: A25687 Encl.: As above Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 MUFG Intime India Private Limited (Formerly Link Intime India Private Limited) CIN: U67190MH1999PTC118368 Block No 202, 2nd Floor, Akshay Complex, Off Dhole Patil Road, Pune - 411001 Tel : +91 20 26161629 Website: https://in.mpms.mufg.com SEBI Registration no.: INR000004058 Date: October 12, 2026 Emcure Pharmaceuticals Limited Plot No. P-1 and P-2. IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune 411057 Maharashtra, India Subject: Confirmation Certificate in the matter of Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. Dear Sir/Madam, With reference to the above-mentioned regulation, we hereby confirm that we did not receive any securities for dematerialization during the quarter ended 30th September 2026. We request you to kindly take note of the above in your records. Thanking You, Yours faithfully, For MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited) Ashok Shetty Vice President – Corporate Registry Part of MUFG Pension & Market Services C-101, Embassy 247, L. B. S. Marg, Vikhroli (West), Mumbai - 400 083. Tel. : +91 22 4918 6000.